
Sign up to save your podcasts
Or
The advent of immunotherapies is transforming cancer care. While early efforts have focused on enabling T cells to attack cancers, Myeloid Therapeutics is developing next-generation immunotherapies that use mRNA to train myeloid cells to attack cancer. We spoke to Daniel Getts, founder and CEO of Myeloid Therapeutics, about the limitations of existing immunotherapies, the role myeloid cells play in the immune system, and the benefits of the company’s therapeutic approach.
3.7
3939 ratings
The advent of immunotherapies is transforming cancer care. While early efforts have focused on enabling T cells to attack cancers, Myeloid Therapeutics is developing next-generation immunotherapies that use mRNA to train myeloid cells to attack cancer. We spoke to Daniel Getts, founder and CEO of Myeloid Therapeutics, about the limitations of existing immunotherapies, the role myeloid cells play in the immune system, and the benefits of the company’s therapeutic approach.
10,367 Listeners
122 Listeners
1,726 Listeners
9,181 Listeners
317 Listeners
6,739 Listeners
59 Listeners
87 Listeners
29 Listeners
147 Listeners
109 Listeners
15,216 Listeners
10 Listeners
47 Listeners
37 Listeners